- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07392892
위식도암에서 화학요법과 함께 PF-08634404라는 연구 의약품에 대해 알아보기 위한 연구
화학요법과 병용 투여되는 PF-08634404의 국소 진행성 또는 전이성 위암, 위식도 접합부암 또는 식도 선암 치료 경험이 없는 환자를 대상으로 한 2상/3상 중재 연구
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to other parts of the body.
To join the study, participants must meet the following conditions:
Be 18 years or older. Have locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma Be treatment naïve for advanced or metastatic disease Be in good physical condition and have healthy organs based on medical tests.
The study has two parts:
- In the first part, researchers will check how safe the study medicine in combination with chemotherapy is and how well people respond to it.
- In the second part, they will compare study medicine plus chemotherapy to another approved treatment (nivolumab plus chemotherapy) to see which works better.
The treatment will be given in repeated time periods called cycles.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 2 단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Pfizer CT.gov Call Center
- 전화번호: 1-800-718-1021
- 이메일: ClinicalTrials.gov_Inquiries@pfizer.com
연구 장소
-
-
-
Tainan, 대만, 704302
- 모병
- National Cheng Kung University Hospital
-
Taipei, 대만, 10002
- 모병
- National Taiwan University Hospital
-
Taipei, 대만, 11217
- 모병
- Taipei Veterans General Hospital
-
-
-
-
California
-
Atascadero, California, 미국, 93422
- 모병
- UCLA Hematology/Oncology - Atascadero
-
Burbank, California, 미국, 91505
- 모병
- UCLA Hematology/Oncology - Burbank
-
Encino, California, 미국, 91436
- 모병
- UCLA Hematology/Oncology - Encino
-
Marina del Rey, California, 미국, 90292
- 모병
- UCLA Hematology/Oncology - Marina del Rey
-
Porter Ranch, California, 미국, 91326
- 모병
- UCLA Hematology/Oncology - Porter Ranch
-
San Francisco, California, 미국, 94158
- 아직 모집하지 않음
- UCSF Helen Diller Family Comprehensive Cancer Center
-
San Francisco, California, 미국, 94158
- 아직 모집하지 않음
- UCSF Investigational Drugs Pharmacy
-
San Luis Obispo, California, 미국, 93401
- 모병
- UCLA Hematology/Oncology - San Luis Obispo
-
Santa Barbara, California, 미국, 93101
- 모병
- UCLA Hematology/Oncology - Santa Barbara
-
Santa Monica, California, 미국, 90404
- 모병
- UCLA Hematology/Oncology - Santa Monica
-
-
Colorado
-
Aurora, Colorado, 미국, 80012
- 모병
- Rocky Mountain Cancer Centers, LLP
-
Boulder, Colorado, 미국, 80303
- 모병
- Rocky Mountain Cancer Centers, LLP
-
Centennial, Colorado, 미국, 80112
- 모병
- Rocky Mountain Cancer Centers, LLP
-
Colorado Springs, Colorado, 미국, 80907
- 모병
- Rocky Mountain Cancer Centers, LLP
-
Colorado Springs, Colorado, 미국, 80923
- 모병
- Rocky Mountain Cancer Centers, LLP
-
Denver, Colorado, 미국, 80218
- 모병
- Rocky Mountain Cancer Centers, LLP
-
Denver, Colorado, 미국, 80220
- 모병
- Rocky Mountain Cancer Centers, LLP
-
Englewood, Colorado, 미국, 80113
- 모병
- Rocky Mountain Cancer Centers, LLP
-
Lakewood, Colorado, 미국, 80228
- 모병
- Rocky Mountain Cancer Centers, LLP
-
Littleton, Colorado, 미국, 80120
- 모병
- Rocky Mountain Cancer Centers, LLP
-
Lone Tree, Colorado, 미국, 80124
- 모병
- Rocky Mountain Cancer Centers, LLP
-
Longmont, Colorado, 미국, 80504
- 모병
- Rocky Mountain Cancer Centers, LLP
-
Pueblo, Colorado, 미국, 81003
- 모병
- Rocky Mountain Cancer Centers, LLP
-
Thornton, Colorado, 미국, 80260
- 모병
- Rocky Mountain Cancer Centers, LLP
-
-
Florida
-
Daytona Beach, Florida, 미국, 32117
- 아직 모집하지 않음
- Florida Cancer Specialists
-
Fleming Island, Florida, 미국, 32003
- 아직 모집하지 않음
- Florida Cancer Specialists
-
Palm Beach Gardens, Florida, 미국, 33410
- 아직 모집하지 않음
- Florida Cancer Specialists
-
Sebring, Florida, 미국, 33870
- 아직 모집하지 않음
- Florida Cancer Specialists
-
Wellington, Florida, 미국, 33414
- 아직 모집하지 않음
- Florida Cancer Specialists
-
West Palm Beach, Florida, 미국, 33401
- 아직 모집하지 않음
- Florida Cancer Specialists
-
-
Illinois
-
Arlington Heights, Illinois, 미국, 60005
- 모병
- Illinois Cancer Specialists
-
Bloomington, Illinois, 미국, 61704
- 모병
- Illinois CancerCare - Bloomington
-
Chicago, Illinois, 미국, 60631
- 모병
- Illinois Cancer Specialists
-
Galesburg, Illinois, 미국, 61401
- 모병
- Illinois CancerCare - Galesburg
-
Niles, Illinois, 미국, 60714
- 모병
- Illinois Cancer Specialists
-
Ottawa, Illinois, 미국, 61350
- 모병
- Illinois CancerCare-Ottawa-Fox River Cancer Center
-
Pekin, Illinois, 미국, 61554
- 모병
- Illinois CancerCare-Pekin
-
Peoria, Illinois, 미국, 61615
- 모병
- Illinois CancerCare, P.C.
-
Peru, Illinois, 미국, 61354
- 모병
- Illinois CancerCare-Peru - Valley Regional Cancer Center
-
Washington, Illinois, 미국, 61571
- 모병
- Illinois CancerCare-Washington
-
-
Maryland
-
Annapolis, Maryland, 미국, 21401
- 모병
- Maryland Oncology Hematology, P.A.
-
Bethesda, Maryland, 미국, 20817
- 모병
- Maryland Oncology Hematology, P.A.
-
Brandywine, Maryland, 미국, 20613
- 모병
- Maryland Oncology Hematology, P.A.
-
Columbia, Maryland, 미국, 21044
- 모병
- Maryland Oncology Hematology, P.A.
-
Germantown, Maryland, 미국, 20876
- 모병
- Maryland Oncology Hematology, P.A.
-
Largo, Maryland, 미국, 20774
- 모병
- Maryland Oncology Hematology, P.A.
-
Rockville, Maryland, 미국, 20850
- 모병
- Maryland Oncology Hematology, P.A.
-
Silver Spring, Maryland, 미국, 20904
- 모병
- Maryland Oncology Hematology, P.A.
-
-
Nevada
-
Reno, Nevada, 미국, 89502
- 모병
- Renown Regional Medical Center
-
Reno, Nevada, 미국, 89502
- 모병
- Renown Health Medical Oncology
-
Reno, Nevada, 미국, 89502
- 모병
- Renown Office of Clinical Research
-
-
New Jersey
-
Morristown, New Jersey, 미국, 07960
- 아직 모집하지 않음
- Atlantic Health System
-
Summit, New Jersey, 미국, 07901
- 아직 모집하지 않음
- Atlantic Health System / Overlook Medical Center
-
-
New York
-
Long Island City, New York, 미국, 11101
- 모병
- Memorial Sloan Kettering Cancer Center Pharmacy (IMP ship to address)
-
Long Island City, New York, 미국, 11101
- 모병
- Memorial Sloan Kettering Cancer Center Pharmacy (IMP storage location)
-
New York, New York, 미국, 10065
- 모병
- Memorial Sloan Kettering Cancer Center - Main Campus
-
New York, New York, 미국, 10021
- 모병
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
-
New York, New York, 미국, 10022
- 모병
- Rockefeller Outpatient Pavilion (53rd Street)
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45245
- 모병
- Oncology Hematology Care Clinical Trials, LLC
-
Cincinnati, Ohio, 미국, 45242
- 모병
- Oncology Hematology Care Clinical Trials, LLC
-
Cincinnati, Ohio, 미국, 45211
- 모병
- Oncology Hematology Care Clinical Trials, LLC
-
Fairfield, Ohio, 미국, 45014
- 모병
- Oncology Hematology Care Clinical Trials, LLC
-
-
Pennsylvania
-
Bensalem, Pennsylvania, 미국, 19020
- 모병
- Alliance Cancer Specialists, PC
-
Doylestown, Pennsylvania, 미국, 18901
- 모병
- Alliance Cancer Specialists, PC
-
Horsham, Pennsylvania, 미국, 19044
- 모병
- Alliance Cancer Specialists, PC
-
Langhorne, Pennsylvania, 미국, 19047
- 모병
- Alliance Cancer Specialists, PC
-
Media, Pennsylvania, 미국, 19063
- 모병
- Alliance Cancer Specialists, PC
-
Sellersville, Pennsylvania, 미국, 18960
- 모병
- Alliance Cancer Specialists, PC
-
Wynnewood, Pennsylvania, 미국, 19096
- 모병
- Alliance Cancer Specialists, PC
-
-
Texas
-
Irving, Texas, 미국, 75063
- 모병
- US Oncology Investigational Products Center (IPC)
-
-
Virginia
-
Arlington, Virginia, 미국, 22201
- 모병
- Virginia Cancer Specialists, PC
-
Chesapeake, Virginia, 미국, 23320
- 모병
- Virginia Oncology Associates
-
Fairfax, Virginia, 미국, 22031
- 모병
- Virginia Cancer Specialists, PC
-
Hampton, Virginia, 미국, 23666
- 모병
- Virginia Oncology Associates
-
Manassas, Virginia, 미국, 20110
- 모병
- Virginia Cancer Specialists, PC
-
Newport News, Virginia, 미국, 23606
- 모병
- Virginia Oncology Associates
-
Norfolk, Virginia, 미국, 23502
- 모병
- Virginia Oncology Associates
-
Reston, Virginia, 미국, 20190
- 모병
- Virginia Cancer Specialists, PC
-
Virginia Beach, Virginia, 미국, 23456
- 모병
- Virginia Oncology Associates
-
Woodbridge, Virginia, 미국, 22191
- 모병
- Virginia Cancer Specialists, PC
-
-
Washington
-
Seattle, Washington, 미국, 98195
- 모병
- University of Washington Medical Center
-
Seattle, Washington, 미국, 98109
- 모병
- Fred Hutchinson Cancer Center
-
Seattle, Washington, 미국, 98104
- 모병
- Harborview Medical Center
-
-
-
-
Barcelona [barcelona]
-
Barcelona, Barcelona [barcelona], 스페인, 08035
- 모병
- Hospital Universitari Vall d'Hebron
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, 스페인, 28041
- 모병
- Hospital Universitario 12 de Octubre
-
-
Ourense [orense]
-
Ourense, Ourense [orense], 스페인, 32005
- 아직 모집하지 않음
- Complexo Hospitalario Universitario de Ourense
-
-
-
-
Central District
-
Petah Tikva, Central District, 이스라엘, 4941492
- 모병
- Rabin Medical Center
-
-
HA Merkaz
-
Ramat Gan, HA Merkaz, 이스라엘, 5265601
- 모병
- Sheba Medical Center
-
-
TELL ABĪB
-
Tel Aviv, TELL ABĪB, 이스라엘, 6423906
- 모병
- Sourasky Medical Center
-
-
-
-
-
Milan, 이탈리아, 20141
- 모병
- Istituto Europeo di Oncologia IRCCS
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, 일본, 464-8681
- 모병
- Aichi Cancer Center
-
-
-
-
Guangdong
-
Guangzhou, Guangdong, 중국, 510655
- 모병
- The Sixth Affiliated hospital, Sun Yat-sen University
-
-
Hubei
-
Wuhan, Hubei, 중국, 430079
- 모병
- Hubei Cancer Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 200031
- 모병
- Zhongshan Hospital,Fudan University
-
-
Sichuan
-
Chengdu, Sichuan, 중국, 610041
- 모병
- Sichuan Cancer hospital
-
-
-
-
Ontario
-
London, Ontario, 캐나다, N6A 5W9
- 아직 모집하지 않음
- London Health Sciences Centre - Verspeeten Family Cancer Centre
-
-
-
-
-
Bayamón, 푸에르토 리코, 00959
- 모병
- Pan American Center for Oncology Trials, LLC - Bayamón Office
-
-
United States
-
Manati, United States, 푸에르토 리코, 00674
- 모병
- Pan American Center for Oncology Trials, LLC - Manati Office
-
-
-
-
-
Paris, 프랑스, 75015
- 모병
- Hôpital Européen Georges Pompidou
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Histological or cytological confirmed gastric, gastroesophageal junction or esophageal adenocarcinoma.
- Evidence of locally advanced or metastatic disease.
- Eastern Cooperative Oncology Group performance status (ECOG) 0-1
- No prior systemic therapy for advanced or metastatic disease.
- Adequate hepatic, liver, and renal function
- HER-2 negative status based on local testing
- PD-L1 positive status based on local testing
Exclusion Criteria:
- Participants with known active CNS metastases, including leptomeningeal, brainstem, meningeal, or spinal cord metastases or compression
- Clinically significant risk of hemorrhage or fistula
- Major surgery or severe trauma within 4 weeks prior to the first dose, or planned major surgery during the study
- History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Any Grade ≥3 bleeding/hemorrhage events within 28 days of Cycle 1 Day 1, or prior history of clinically significant bleeding events
- Clinically significant cardiovascular disease, or other comorbidities, within 6 months prior to first dose
- Participants with active autoimmune diseases requiring systemic treatment within the past 2 years
- Evidence of non-infectious or drug-induced interstitial lung disease (ILD) pneumonitis
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Phase 2 Portion
PF-08634404 + Chemotherapy |
Participants will receive PF-08634404 intravenously.
다른 이름들:
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. |
|
실험적: Phase 3: Arm A
PF-08634404 + Chemotherapy |
Participants will receive PF-08634404 intravenously.
다른 이름들:
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. |
|
활성 비교기: Phase 3: Arm B
Nivolumab + Chemotherapy |
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. Participants will receive Nivolumab intravenously. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Phase 2: Confirmed Objective response rate (ORR) using RECIST 1.1 as assessed by investigator
기간: Approximately 4 years
|
Confirmed ORR by investigator is defined as the proportion of participants with confirmed Complete Response (CR) or Partial Response (PR) per RECIST v1.1 as assessed by investigator. |
Approximately 4 years
|
|
Phase 2: Number of participants with treatment-emergent adverse events
기간: Through 90 days after the last study intervention; Approximately 4 years
|
Adverse Events (AEs) as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Progression Free Survival (PFS) using RECIST 1.1 as assessed by BICR
기간: Approximately 4 years
|
PFS by BICR is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: Overall Survival (OS)
기간: Approximately 4 years
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Approximately 4 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
2상: PF-08634404에 대한 항약물항체(ADA) 발생률
기간: 약 21개월
|
약 21개월
|
|
|
3상: PF-08634404에 대한 ADA 발생률
기간: 약 21개월
|
약 21개월
|
|
|
3상: Functional Assessment of Cancer Therapy - Gastric(FACT-Ga) 총점의 기준선 대비 변화
기간: 약 4년
|
약 4년
|
|
|
3상: FACT-Ga 총 점수의 확정적 악화까지의 시간
기간: 약 4년
|
약 4년
|
|
|
3상: Gastric Cancer Subscale (GaCS) 점수의 확정적 악화까지의 시간
기간: 약 4년
|
약 4년
|
|
|
Phase 2: Duration of Response (DOR) using RECIST 1.1 as assessed by investigator
기간: Approximately 4 years
|
DOR by investigator is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 2: Progression Free Survival (PFS) using RECIST 1.1 as assessed by investigator
기간: Approximately 4 years
|
PFS by investigator is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 2: Overall Survival (OS)
기간: Approximately 4 years
|
OS is defined as the time from the date of first dose to the date of death due to any cause. |
Approximately 4 years
|
|
Phase 2: Number of participants with laboratory abnormalities
기간: Through 90 days after the last study intervention; Approximately 4 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 2: Serum concentrations of PF-08634404
기간: Approximately 21 months
|
Predose and postdose concentrations of PF-08634404 |
Approximately 21 months
|
|
Phase 3: ORR using RECIST 1.1 as assessed by BICR
기간: Approximately 4 years
|
ORR by BICR is defined as the proportion of participants with a Best Overall Response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 as assessed by BICR. |
Approximately 4 years
|
|
Phase 3: ORR using RECIST 1.1 as assessed by investigator
기간: Approximately 4 years
|
ORR by investigator is defined as the proportion of participants with a BOR of confirmed CR or confirmed PR per RECIST 1.1 as assessed by investigator. |
Approximately 4 years
|
|
Phase 3: Progression free survival (PFS) using RECIST 1.1 as assessed by investigator
기간: Approximately 4 years
|
PFS by investigator is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first |
Approximately 4 years
|
|
Phase 3: DOR using RECIST 1.1 as assessed by BICR
기간: Approximately 4 years
|
DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: DOR using RECIST 1.1 as assessed by investigator
기간: Approximately 4 years
|
DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: PFS2 (PFS after next-line therapy) by investigator
기간: Approximately 4 years
|
PFS2 is defined as the time from the date of randomization to the date of second objective disease progression or death due to any cause, whichever occurs first |
Approximately 4 years
|
|
Phase 3: Number of participants with treatment-emergent adverse events
기간: Through 90 days after the last study intervention; Approximately 4 years
|
AEs as characterized by type, frequency, intensity as graded by NCI CTCAE version 5.0, timing, seriousness, and relationship to study intervention(s) |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Number of participants with laboratory abnormalities
기간: Through 90 days after the last study intervention; Approximately 4 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Serum concentrations of PF-08634404
기간: Approximately 21 months
|
Predose and postdose concentrations of PF-08634404 |
Approximately 21 months
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Pfizer CT.gov Call Center, Pfizer
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- C6461016
- 2025-524717-86-00 (레지스트리 식별자: CTIS (EU))
- 2025 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .